title: Therapeutic potential of HDL in cardioprotection and tissue repair.
abstract: Epidemiological studies support a strong association between high-density lipoprotein (HDL) cholesterol levels and heart failure incidence. Experimental evidence from different angles supports the view that low HDL is unlikely an innocent bystander in the development of heart failure. HDL exerts direct cardioprotective effects, which are mediated via its interactions with the myocardium and more specifically with cardiomyocytes. HDL may improve cardiac function in several ways. Firstly, HDL may protect the heart against ischaemia/reperfusion injury resulting in a reduction of infarct size and thus in myocardial salvage. Secondly, HDL can improve cardiac function in the absence of ischaemic heart disease as illustrated by beneficial effects conferred by these lipoproteins in diabetic cardiomyopathy. Thirdly, HDL may improve cardiac function by reducing infarct expansion and by attenuating ventricular remodelling post-myocardial infarction. These different mechanisms are substantiated by in vitro, ex vivo, and in vivo intervention studies that applied treatment with native HDL, treatment with reconstituted HDL, or human apo A-I gene transfer. The effect of human apo A-I gene transfer on infarct expansion and ventricular remodelling post-myocardial infarction illustrates the beneficial effects of HDL on tissue repair. The role of HDL in tissue repair is further underpinned by the potent effects of these lipoproteins on endothelial progenitor cell number, function, and incorporation, which may in particular be relevant under conditions of high endothelial cell turnover. Furthermore, topical HDL therapy enhances cutaneous wound healing in different models. In conclusion, the development of HDL-targeted interventions in these strategically chosen therapeutic areas is supported by a strong clinical rationale and significant preclinical data.
authors.affiliation: Charité-University-Medicine Berlin, Campus Virchow, Berlin-Brandenburg Center for Regenerative Therapy (BCRT), Berlin, Germany.
authors.forename: Sophie
authors.initials: S
authors.lastname: Van Linthout
authors.forename: Miguel
authors.initials: M
authors.lastname: Frias
authors.forename: Neha
authors.initials: N
authors.lastname: Singh
authors.forename: Bart
authors.initials: B
authors.lastname: De Geest
mesh_terms: D000287:Administration, Topical; D000818:Animals; D016632:Apolipoprotein A-I / Q000096:biosynthesis* / Q000235:genetics; D018955:CD36 Antigens / Q000378:metabolism; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D058065:Diabetic Cardiomyopathies / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D042783:Endothelial Cells / Q000378:metabolism / Q000473:pathology; D015316:Genetic Therapy; D006801:Humans; D008075:Lipoproteins, HDL / Q000008:administration & dosage / Q000627:therapeutic use*; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D012038:Regeneration; D012867:Skin / Q000187:drug effects / Q000473:pathology; D013234:Stem Cells / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
chemical_list: C505693:APOA1 protein, human; D016632:Apolipoprotein A-I; D018955:CD36 Antigens; D002317:Cardiovascular Agents; D008075:Lipoproteins, HDL